|
New Research Reports
Displaying: All Topics
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
The Market for Home Care Products, 7th Edition
The Worldwide Market for In Vitro Diagnostic Tests, 8th Edition (pre-publication)
White Paper: Why Hospitals are Choosing Handhelds
The Global Market for Medical Devices, 3rd. Edition
Recent Press Releases
Medical Device Market Looks to Innovations to Counter Cost Cuts: Kalorama
Over-the-Counter Drug Sales Saw Little Boost From Recession: Kalorama
Kalorama Report Describes Challenges for the Clinical Lab Business
Competitive Bidding Will Dampen Sales Growth for Home Care Products
EMR Opportunity Seen in Targeting Physicians with Web-Based Products
Opportunity for Drug Makers in Products that Assist Anesthesia Process
Kalorama Information: Tests That Personalize Results Show Sales Growth of Up To 38%
Weak Flu Market Shouldn't Affect Vaccine Sales: Kalorama
Long Term Care Industry Grew 5.5% in Past Five Years: Kalorama
Six Companies Lead EMR Market: Kalorama
|
Kalorama Information
Kalorama's handhelds in healthcare report cited in FierceHealthIT article on physician use of online continuing ed training
More >
Wall Street Journal's Health Blog cites Kalorama’s wound care market numbers in a special report on innovation in health care
More >
Healthcare Finance News Penned an Article on Kalorama's New EMR Report, Citing Market Growth
More >
Kalorama's New Report EMR 2012 Featured in Healthcare Finance News
More >
Genetic Engineering News Article Cites Kalorama Antifungal Market Data
More >
in the News
|
||||||||||||||||||||||
|
Privacy Policy
|
Terms and Conditions
|
Site Map
|
Return Policy
|
Press
|
Help FAQs
|
Reimbursement woes have slowed down the market for clinical lab services in the United States, according to Kalorama Information. The healthcare market research publisher said the market was worth approximately $52.1 billion in 2011, increasing just 1.6% from $51.3 billion in 2010. Several indictors are favorable to the growth of the testing market, but reductions in reimbursement have negatively impacted what labs can earn. This finding was made in Kalorama's most recent report on the subject, 